Iridex's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period
Return on Investment, Quarterly Results, Trends, Rankings, Statistics
What is Iridex's ROI in the second quarter of 2026?
Iridex Corp recorded a cumulative net loss of $-4 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -23.09%.
Within the Healthcare sector 183 other companies had a higher return on investment. While Return on investment, overall ranking has progressed in the Jul 04 2026 quarter, so far to 3203, from total ROI ranking in the first quarter of 2026 at 3417.
In a landscape marked by rapid technological advancements and fierce competition, Iridex Corporation (NASDAQ: IRIX), a prominent player in the medical device industry, has found itself at a crossroads. Founded with the vision of revolutionizing the treatment of glaucoma and retinal diseases through innovative laser-based medical systems and delivery devices, the company is now grappling with stark financial realities. Preliminary Financial ResultsAs of April 14, 2025, Iridex disclosed preliminary unaudited operational and financial results for the first quarter ending March 29, 2025. These results paint a concerning picture: a cumulative net loss of $9 million during the last twelve months leading up to the fourth quarter of 2024, which culminated in a dramatic return on investment (ROI) of -186.17%. Such figures are alarming, suggesting that the company s efforts to establish itself as a leader in an increasingly competitive sector may be falling short.
ArticleIn a bold move that underscores both the potential and precarious state of Iridex Corporation (NASDAQ: IRIX), the Mountain View-based company recently closed a strategic investment deal worth $10 million, backed by Novel Inspiration International Co. Ltd. This investment raises questions about Iridex’s financial sustainability and its ability to capitalize on groundbreaking innovation in the competitive healthcare market.Founded in 2020, Novel Inspiration is led by William Moore, a familiar face in Iridex’s boardroom, having served both as a board member and the company’s Chief Executive Officer. This connection raises eyebrows—was this deal a lifeline or merely a stopgap measure to stave off financial distress? The additional option for up to $10 million in future funding appears attractive on the surface but may reflect deeper issues within the company’s financial health.
Iridex Faces Stock Market Turbulence Amid Groundbreaking Innovation in Glaucoma TreatmentBy CSI Market MOUNTAIN VIEW, Calif. — In the face of considerable stock price volatility, Iridex Corporation (NASDAQ: IRIX), a recognized leader in laser-based medical systems for glaucoma and retinal diseases, has publicly addressed its recent financial struggles while simultaneously spotlighting its innovations in glaucoma treatment. This dual narrative presents a company at a crossroads, where groundbreaking advances in medical technology contend with substantial financial challenges.According to the most recent financial data, Iridex recorded a substantial cumulative net loss of $11 million for the 12 months ending in the third quarter of 2024, casting a long shadow over its profitability. With a negative return on investment (ROI) of -118.7%, the company has fallen behind its competitors. Within the healthcare sector, 553 other firms have managed to achieve higher ROI figures, leading to a notable drop in Iridex’s total ranking from 3622 to 3697 in just a matter of months, raising concerns among investors about the long-term viability of its innovative offerings.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
